PT  - JOURNAL ARTICLE
AU  - Amal Imbulgoda
AU  - Anthony MacLean
AU  - John Heine
AU  - Sebastien Drolet
AU  - Michael M. Vickers
TI  - Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review
AID  - 10.1503/cjs.013014
DP  - 2015 Jun 01
TA  - Canadian Journal of Surgery
PG  - 167--171
VI  - 58
IP  - 3
4099  - http://canjsurg.ca/content/58/3/167.short
4100  - http://canjsurg.ca/content/58/3/167.full
SO  - CAN J SURG2015 Jun 01; 58
AB  - Background: Self-expanding metal stents (SEMS) are increasingly used in the treatment of malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is a well-known complication associated with these devices. The addition of the vascular endothelial growth factor inhibitor bevacizumab is suspected to increase the rate, but the extent of the increase is not known.Methods: We retrospectively reviewed the records of patients receiving SEMS in tertiary hospitals in Calgary, Alta., between October 2001 and January 2012.Results: We reviewed the records of 87 patients with inoperable colorectal cancer who received SEMS during our study period. Nine perforations occurred in total: 4 of 30 (13%) patients who received no chemotherapy, 3 of 47 (6%) who received chemotherapy but no bevacizumab, and 2 of 10 (20%) who received chemotherapy and bevacizumab. These two patients received bevacizumab with FOLFIRI after SEMS placement, and they had peritoneal disease.Conclusion: Our case series and other studies suggest that bevacizumab may increase the risk of colonic perforation in the setting of SEMS. Caution should be used when combining these therapies.